Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy by Mellors, John W. et al.
TREATMENT WITH INDINAVIR, ZIDOVUDINE, AND LAMIVUDINE IN ADULTS 
WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND PRIOR 
ANTIRETROVIRAL THERAPY
ROY M. GULICK, M.D., M.P.H., JOHN W. MELLORS, M.D., DIANE HAVLIR, M.D., JOSEPH J. ERON, M.D., 
CHARLES GONZALEZ, M.D., DEBORAH MCMAHON, M.D., DOUGLAS D. RICHMAN, M.D., FRED T. VALENTINE, M.D., 
LESLIE JONAS, B.S., ANNE MEIBOHM, PH.D., EMILIO A. EMINI, PH.D., AND JEFFREY A. CHODAKEWITZ, M.D.
ABSTRACT
Background The new protease inhibitors are po-
tent inhibitors of the human immunodeficiency virus 
(HIV), and in combination with other antiretroviral 
drugs they may be able to cause profound and sus-
tained suppression of HIV replication.
Methods In this double-blind study, 97 HIV-infect-
ed patients who had received zidovudine treatment 
for at least 6 months and had 50 to 400 CD4 cells per 
cubic millimeter and at least 20,000 copies of HIV 
RNA per milliliter were randomly assigned to one of 
three treatments for up to 52 weeks: 800 mg of indin-
avir every eight hours; 200 mg of zidovudine every 
eight hours combined with 150 mg of lamivudine 
twice daily; or all three drugs. The patients were fol-
lowed to monitor the occurrence of adverse events 
and changes in viral load and CD4 cell counts.
Results The decrease in HIV RNA over the first 24 
weeks was greater in the three-drug group than in 
the other groups (P0.001 for each comparison). 
RNA levels decreased to less than 500 copies per 
milliliter at week 24 in 28 of 31 patients in the three-
drug group (90 percent), 12 of 28 patients in the in-
dinavir group (43 percent), and none of 30 patients 
in the zidovudine–lamivudine group. The increase in 
CD4 cell counts over the first 24 weeks was greater 
in the two groups receiving indinavir than in the zi-
dovudine–lamivudine group (P0.01 for each com-
parison). The changes in the viral load and the CD4 
cell count persisted for up to 52 weeks. All the regi-
mens were generally well tolerated.
Conclusions In most HIV-infected patients with 
prior antiretroviral therapy, the combination of indin-
avir, zidovudine, and lamivudine reduces levels of 
HIV RNA to less than 500 copies per milliliter for as 
long as one year. (N Engl J Med 1997;337:734-9.)
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OMBINATION therapy with two nucleo-
side analogues is better than monotherapy
in reducing levels of human immunodefi-
ciency virus (HIV) RNA, increasing CD4
cell counts, and preventing the acquired immunode-
ficiency syndrome (AIDS) and death.1-5 The HIV-
protease inhibitors are a newer class of agents with 
potent antiretroviral activity.6-9 Early dose-escalation 
studies showed that monotherapy with indinavir or 
ritonavir affected HIV RNA levels and CD4 cell 
counts markedly.10-12 These antiretroviral effects were 
transient in some patients at lower drug doses and
C
were associated with the emergence of drug-resist-
ant virus.13-15 A recent study showed that a combina-
tion of zidovudine, zalcitabine, and saquinavir had
more antiretroviral activity than zidovudine com-
bined with either zalcitabine or saquinavir, although
the treatment effects were relatively small and tran-
sient.16
Because of the potent antiretroviral activity of in-
dinavir8,12 and the sustained antiretroviral effects of
the combination of zidovudine and lamivudine,1,2
we decided to study regimens designed for maximal
suppression of HIV replication. We compared the
safety and antiretroviral activity of three treatments
— indinavir alone, zidovudine and lamivudine in
combination, and all three drugs together — in a




Adults who were seropositive for HIV type 1 and who had at
least six months of prior zidovudine therapy were screened for en-
rollment at four sites. They were eligible for the study if they had
a serum HIV RNA level of at least 20,000 copies per milliliter
(Amplicor HIV Monitor test, Roche Diagnostics Systems, Branch-
burg, N.J.) at the time of screening and 50 to 400 CD4 cells per
cubic millimeter when the values obtained in two determinations
at least one week apart were averaged. Additional criteria for en-
rollment included a hemoglobin level exceeding 9.0 g per decili-
ter (in men) or 8.5 g per deciliter (in women), a neutrophil count
greater than 1000 per cubic millimeter, a platelet count of at least
100,000 per cubic millimeter, a serum creatinine level less than
1.5 times the upper limit of normal, a total bilirubin level in the
normal range, and levels of hepatic aminotransferases and alkaline
phosphatase less than 2 times the upper limit of normal.
Patients were excluded if they had received lamivudine or any
HIV-protease inhibitor, if they required maintenance therapy for
an opportunistic infection, or if they had received investigational
or immunomodulatory drugs within 30 days before entry into the
study. Also excluded were pregnant or breast-feeding women, as
were patients with active substance abuse, hepatitis B surface an-
tigenemia, substantial elevations of hepatic aminotransferases in
the prior year, or intolerance to zidovudine. Patients were permit-
ted to take prophylaxis for Pneumocystis carinii pneumonia.
Study Design
This was a randomized, double-blind, controlled study of the
safety and activity of three antiretroviral regimens. Randomiza-
tion followed a permuted-block design stratified according to site
and CD4 cell count (either 50 to 250 or 251 to 400 cells per
cubic millimeter). The planned duration of the double-blind
study was 52 weeks, but because there were preliminary findings
of antiretroviral activity, the study design was amended to provide
open-label therapy with all three drugs after a minimum of 24
weeks of blinded, randomized therapy. This change resulted in
periods of blinded, randomized treatment of varying lengths,
from 24 weeks to 52 weeks. Only data corresponding to the
blinded portion of the study are presented here. All the patients
continued to be monitored while they were receiving open-label
therapy. The study was approved by the internal review boards at
each site, and all the patients gave written informed consent.
Treatment Regimens
Eligible patients discontinued their antiretroviral therapy two
weeks before entry and were then randomly assigned one of three
regimens given orally: 800 mg of indinavir (Crixivan, Merck,
West Point, Pa.) every 8 hours; 200 mg of zidovudine (Retrovir,
Glaxo–Wellcome, Research Triangle Park, N.C.) every 8 hours
combined with 150 mg of lamivudine (Epivir, Glaxo–Wellcome)
every 12 hours; or all three drugs at the same doses. The regi-
mens included appropriate matching placebos.
Assessments
The patients were assessed weekly for four weeks, every two
weeks through week 16, and every four weeks through week 52.
At base line and each study visit, the medical history was re-
viewed, a physical examination was performed, and standardized
laboratory tests were conducted. A pregnancy test of serum was
performed in eligible women before the study and every four
weeks thereafter. Blood samples were collected from a subgroup
of patients on day 8 to determine plasma drug concentrations. Pa-
tients who discontinued the study were reevaluated two weeks af-
ter their last dose of the study drugs. Adverse events were man-
aged by investigators unaware of the treatment assignments, using
predetermined guidelines.
Virologic and Immunologic Studies
Samples were obtained at screening, at base line, and at each
study visit. Serum was processed, stored at 70°C, and assayed
later for HIV RNA by a quantitative reverse-transcriptase–poly-
merase-chain-reaction (PCR) assay (Amplicor test). The lower
limit of quantification was 500 RNA copies per milliliter. The as-
say results were reported as values when there were 500 or more
copies per milliliter or as “less than 500 copies per milliliter,” or
as “negative” if no amplification signal was detected. An investi-
gational version of an ultrasensitive PCR assay was performed on
samples in which the standard assay detected a level of less than
500 copies per milliliter. This assay had a consistent cutoff of de-
tection of approximately 50 RNA copies per milliliter. In the anal-
yses of resistance, viral RNA was extracted from serum, amplified
by PCR, and cloned and sequenced by a previously described
method.13,14 T-lymphocyte subgroups were quantified by flow cy-
tometry.
Statistical Analysis
The primary measures of antiretroviral-drug activity were the
magnitude and duration of changes in serum HIV RNA and CD4
cell counts over a period of 24 weeks, as summarized by an area-
under-the-curve measurement that incorporated the base-line val-
ue.17,18 All the patients with determinations made at base line and
at least once subsequently were included in the analyses. For the
purpose of analysis, RNA values reported as “less than 500 copies
per milliliter” were considered equivalent to 500 copies per mil-
liliter, and values reported as “negative” were considered equiva-
lent to 250 copies per milliliter. The HIV RNA values underwent
a log10 transformation before analysis. The area under the curve
was compared among the treatment groups with an analysis-of-
variance model that included the study treatment and a variable
defined according to site and CD4 stratum. In calculating the
proportion of patients who had HIV RNA levels of less than 50
copies per milliliter by the ultrasensitive investigational assay, we
assumed that patients who had at least 500 RNA copies per mil-
liliter by the standard assay had at least 50 copies per milliliter.
For each pair of treatments, Fisher’s exact test was used to com-
pare the groups with respect to the proportion of patients with
clinical nephrolithiasis, severe drug-related adverse events, and
clinically significant laboratory abnormalities. A clinically signifi-
cant laboratory abnormality was considered to be present if a val-
ue exceeded the predefined criteria or an abnormality present at
base line became worse. The analyses were performed on an in-




Ninety-seven patients were enrolled in the study
from April to December 1995. Initially, 27 patients
were enrolled for a four-week analysis of safety; when
no serious adverse events occurred, the remaining
70 patients were enrolled. The base-line characteris-
tics of the patients were similar in the three treat-
ment groups (Table 1).
Of the 97 patients, 92 were studied on a random-
ized, blinded basis for 24 weeks, 79 for 36 weeks,
and 16 for 52 weeks. The patients switched to open-
label three-drug therapy after a median of 41 weeks
(range, 24 to 52). Seven patients discontinued the
study after 4 to 44 weeks, for various reasons: an ad-
verse event (one patient), loss to follow-up (one),
the use of medications prohibited by the protocol
(two), and the patient’s request (three). There were
no significant differences among the treatment groups
in the rates of discontinuation (P0.35 for each
pairwise comparison).
Pharmacokinetic Analysis
Plasma concentrations of the study drug were
measured in the first 27 patients enrolled in the
study. There were no clinically significant pharmaco-
kinetic interactions among the study medications. 
HIV RNA
Over a 24-week period, serum HIV RNA levels de-
clined in all three groups, with adjusted mean (SE)
decreases (in the area-under-the-curve analysis) of
1.770.11 log10 in the three-drug group, 1.240.11
log10 in the indinavir group, and 0.830.11 log10 in
the zidovudine–lamivudine group (Fig. 1). The de-
crease was significantly greater in the three-drug
group than in the other two groups (P0.001 for
each pairwise comparison). In addition, the decrease
in the indinavir group was significantly greater 
(P0.005) than that in the zidovudine–lamivudine 
group. In the three-drug group there was a median 
reduction of more than 2 log10 in the HIV RNA level 
that lasted from week 8 to week 52. In contrast, after 
initial decreases, the RNA levels increased in both the 
indinavir and zidovudine–lamivudine groups.
Figure 2A shows the proportion of patients in 
each group who had decreases in HIV RNA levels 
to less than 500 copies per milliliter. At week 24, 90 
percent of the patients in the three-drug group (28 
of 31) had levels of less than 500 RNA copies per 
milliliter, as compared with 43 percent of the indin-
avir group (12 of 28 patients) and none of 30 pa-
tients in the zidovudine–lamivudine group. These 
proportions were sustained for up to 52 weeks. Fig-
ure 2B shows the proportion of patients in each 
group whose levels decreased to less than 50 copies 
per milliliter. 
Genotypic Analysis
There was no evidence of resistance to lamivu-
dine19-21 at base line. After 24 weeks of therapy, 84
percent of the zidovudine–lamivudine group (26 of
31) had such resistance, and 53 percent (10 of 19)
of patients with amplifiable RNA in the indinavir
group had mutations conferring resistance to indin-
avir.14 At the same time, 26 of 31 serum samples
from patients in the three-drug group could not be
amplified because of low HIV RNA levels. Of the
five patients in that group who had more than 500
RNA copies per milliliter by week 32, all had virus
with resistance to lamivudine, and three acquired in-
dinavir-resistance mutations.
CD4 Cell Counts
CD4 cell counts increased during the first 24
weeks of treatment in all the groups, with adjusted
mean (SE) increases (in the area-under-the-curve
analysis) of 86.011.9 cells per cubic millimeter in
the three-drug group, 100.612.5 in the indinavir
group, and 46.312.1 in the zidovudine–lamivu-
dine group (Fig. 3). The increase was significantly
greater in the groups assigned to the two regimens
containing indinavir than in the zidovudine–lamivu-
dine group (P0.01 for each comparison). There
*Because of rounding, percentages do not total 100 in every case.
†These drugs included didanosine, zalcitabine, and stavudine.
‡Patients were stratified on the basis of the mean of two CD4 cell counts obtained before the start of the study.
§For one patient in the three-drug group, HIV RNA was not measured before the study treatment began.






















Mean (SD) age — yr 40.18.5 41.47.9 40.28.6 38.78.9

































Prior AIDS-defining illness — 
no. of patients (%)
13 (13) 5 (15) 5 (16) 3 (9)
Use of other approved antiretroviral
drugs — no. of patients (%)†
69 (71) 21 (64) 22 (71) 26 (79)













































was no significant difference between the three-drug
group and the indinavir group over the first 24
weeks (P0.36). The CD4 cell count in each group
remained at approximately the same level from week
24 to week 52.
Adverse Events
The study treatments were generally well tolerated
for up to 52 weeks (Table 2). One patient withdrew
from the study because of an adverse event (nausea).
Elevated bilirubin levels and clinical nephrolithiasis,
defined as pain in the flank with or without hema-
turia or the passage of a stone or gravel in the urine,
occurred more often in the patients receiving indin-
avir. There were no other significant differences
among the groups in the occurrence of severe, drug-
related clinical events or clinically important labora-
tory abnormalities. One new AIDS-defining illness
(presumptive candida esophagitis) occurred in a pa-
tient randomly assigned to zidovudine and lamivu-
dine. There were no deaths among the study pa-
tients.
DISCUSSION
The three-drug combination of indinavir, zidovu-
dine, and lamivudine reduced the viral load in serum
to less than 500 copies per milliliter for up to one
year in more than 80 percent of the HIV-infected
patients we studied, all of whom had prior anti-
retroviral therapy. Most patients in the three-drug
group whose HIV RNA levels were reduced to less
than 500 copies per milliliter also had less than 50
RNA copies per milliliter when the ultrasensitive in-
vestigational assay was used. The sustained response
in HIV RNA levels with the three-drug therapy was
superior to that with either indinavir monotherapy
or the combination of zidovudine and lamivudine.
Figure 1. Changes from Base Line in Serum HIV RNA Levels
during the 52 Weeks of the Study.

































   lamivudine
NO. OF PATIENTS STUDIED
30 30 25 10 5
31 28 25   8 5
33 30 25   9 5
Figure 2. Proportion of Patients with Serum HIV RNA Levels of
Less Than 500 Copies per Milliliter (Upper Panel) and Less
Than 50 Copies per Milliliter (Lower Panel).



























   lamivudine
NO. OF PATIENTS STUDIED
31 31 26 10 5
31 28 25   8 5
33 30 25   9 5








12 24 36 48
HIV RNA 500 copies/ml
Figure 3. Changes from Base Line in the CD4 Cell Count during
the 52 Weeks of the Study.
Median values are shown. Bars are 25th and 75th percentiles.

























   lamivudine
NO. OF PATIENTS STUDIED
31 31 26 10 5
31 27 26   8 5





drugs. Without complete viral suppression, antiret-
roviral regimens will probably select for drug-resist-
ant mutants, leading to the failure of therapy. The
patients we studied had taken neither lamivudine
nor any protease inhibitor before entering the study.
When lamivudine and indinavir were introduced
concurrently as part of the three-drug regimen, they
had potent antiretroviral activity, thus preventing
the development of resistance to lamivudine, which
is typically seen within weeks after the start of la-
mivudine treatment, either alone or with zidovu-
dine.22,23 Patients previously treated with lamivudine
or a protease inhibitor may not have similar sus-
tained benefits with this three-drug regimen.
The reasons for the rebound of serum HIV RNA
levels in a few patients taking the three drugs are not
clear. Among the five patients in the three-drug
group who had more than 500 HIV RNA copies per
milliliter by week 32, all had resistance to lamivudine
and three had resistance to indinavir. One of these five
patients discontinued therapy prematurely, and three
others reported intermittent adherence to the study
regimen. In the fifth patient, the HIV RNA level de-
clined markedly but then increased, with the con-
comitant development of resistance to both lamivu-
dine and indinavir. The rebound in HIV RNA levels
did not appear to be associated with base-line resist-
ance to zidovudine, base-line polymorphisms of viral-
protease residues, or the level of HIV RNA at entry.
This study was designed to compare the treatment
groups with respect to viral load and CD4 cell re-
sponses, not clinical end points. Recent evidence
from natural-history studies and clinical trials links
viral load and clinical outcome.1,2,4,5,24-29 These stud-
ies suggest that the sustained reductions of HIV
RNA we observed will probably translate into de-
layed progression to AIDS and prolonged survival.
The dissociation between the marked decreases in
viral load and the incomplete restoration of CD4
cell counts in the three-drug group remains unex-
plained. Some patients may have ongoing, slower in-
creases in CD4 cell counts after six months of ther-
apy. In patients with autoimmune disease or cancer
who receive intensive radiation therapy or chemo-
therapy, CD4 cell counts recover slowly and may
take three years or more to reach normal levels.30,31
Further study is needed to determine what level of
restoration of CD4 cell number and function can
ultimately be attained with the three-drug regimen.
It remains to be seen whether the immune system
can be fully reconstituted even when regimens that
achieve maximal HIV suppression are used.
All the study treatments were generally well toler-
ated, with only a single patient discontinuing the
blinded portion of the study because of an adverse
event. As expected, the use of indinavir was associ-
ated with episodes of clinical nephrolithiasis and
asymptomatic increases in indirect bilirubin. The pro-
*Patients are counted only once, even if they have two or more episodes
of the same adverse event.
†Clinical nephrolithiasis was defined as flank pain with or without he-
maturia or the passage of a stone or gravel in the urine. There were a total
of 11 episodes in 10 patients. P0.355 for the comparison of the three-
drug group with the zidovudine–lamivudine group, and P0.099 for the
comparison of the indinavir group with the zidovudine–lamivudine group.
‡These were events judged by a blinded investigator to be possibly,
probably, or definitely related to the study treatment.
§To convert values for bilirubin to micromoles per liter, multiply by 17.1.
¶P0.001 for the comparison of the three-drug group with the zidovu-
dine–lamivudine group, and P0.002 for the comparison of the indinavir 
group with the zidovudine–lamivudine group.
No prior antiretroviral regimen has produced the 
marked, sustained decreases in viral load achieved 
with this three-drug combination.
The continued suppression of HIV RNA levels for 
one year without evidence of the emergence of re-
sistant virus suggests that there was little, if any, con-
tinuing HIV replication in the patients receiving 
three-drug therapy. At 24 weeks, high levels of re-
sistance to lamivudine had developed in most of the 
patients receiving zidovudine and lamivudine,19-21 
and over half the patients with amplifiable HIV 
RNA who were receiving indinavir alone had resist-
ance to indinavir.14 In contrast, most patients treated 
with the three-drug combination provided serum 
samples from which HIV RNA could not be ampli-
fied, implying that the virus continued to be suscep-
tible. The durable antiretroviral activity of the three-
drug regimen appears to result directly from the 
inability of resistant virus to emerge.
If there is to be long-term control of HIV infec-
tion, the goal of antiretroviral therapy should be the 
sustained, complete suppression of HIV replication 
and the prevention of resistance to the antiretroviral
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portion of patients who met our definition of neph-
rolithiasis was higher in this study than has previous-
ly been observed.32 To facilitate long-term compliance
with drug regimens, it is essential that the antiretro-
viral drugs be well tolerated.
In summary, the antiretroviral-drug combination
of indinavir, zidovudine, and lamivudine reduced
HIV RNA levels to less than 500 copies per milliliter
in most HIV-infected patients previously treated
with zidovudine for as long as one year. This sug-
gests that profound suppression of HIV replication
inhibits the emergence of drug-resistant virus and
that such inhibition should be an important goal in
the long-term treatment of HIV infection. A regi-
men that falls short of maximal viral suppression will
probably be accompanied by the emergence of drug
resistance and by ultimate clinical failure. The results
of this study support a new standard for the evalua-
tion of antiretroviral therapies and suggest a new
paradigm for the treatment of HIV disease.
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